KFKenji Fujizuka

Kenji Fujizuka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kenji Fujizuka has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • Mitsunobu Nakamura

    Department of Critical Care and Emergency Medicine, Center Japanese Red Cross Maebashi Hospital Maebashi Japan

    4 shared publications
  • Hiroyuki Suzuki

    Advanced Medical Emergency Department and Critical Care Center Japanese Red Cross Maebashi Hospital Maebashi Japan

    3 shared publications
  • Shu Utsumi

    Department of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan

    2 shared publications
  • Yoshihiko Takahashi

    Advanced Medical Emergency Department and Critical Care Centre, Maebashi Red Cross Hospital, Gunma, Japan

    2 shared publications
  • Akira Kawauchi

    Advanced Medical Emergency Department and Critical Care Center Japanese Red Cross Maebashi Hospital Maebashi Japan

    1 shared publication
  • Akiyoshi Nagatomi

    Department of Emergency and Critical Care Medicine St. Marianna University Yokohama City Seibu Hospital Yokohama Japan

    1 shared publication

Latest Publications

  • Open Access

    A case report: Efficacy of thoracic MRA for ischemic stroke due to acute aortic dissection

    by Jun Nagayama, Kenji Fujizuka, Shioya Hayato, Ryosuke Tsuchiya, Mitsunobu Nakamura

    Background: Ischemic stroke requires prompt diagnosis and treatment but rarely results from acute aortic dissection. The administration of tissue‐type plasminogen activator (t‐PA) to such patients can lead to serious complications and potentially fatal outcomes. Here, we report a case in which thoracic magnetic resonance angiography (MRA) was useful for identifying cerebral infarction complicated by acute aortic dissection. Case Presentation: A 60‐year‐old man presented with a sudden onset of left‐sided hemiplegia, right‐sided hemiparesis, and dysarthria. Noncontrast CT ruled out intracranial hemorrhage; however, aortic dissection was not detected. MRI showed reduced blood flow in the right middle cerebral artery, and t‐PA administration was suspected to have caused ischemic stroke. However, thoracic MRA revealed dissection from the ascending aorta to the arch, which was diagnosed using contrast‐enhanced CT. Conclusion: Thoracic MRA is useful for diagnosing acute aortic dissection in patients with a stroke.

  • Open Access

    Veno‐venous extracorporeal membrane oxygenation for acute respiratory distress syndrome caused by nitrogen dioxide inhalation: A case report

    by Tomoya Nishimura, Makoto Aoki, Hiroyuki Suzuki, Hiroya Hagiwara, Akira Kawauchi, Kenji Fujizuka, Mitsunobu Nakamura

    Background: Nitrogen dioxide (NO2) is known to cause lung injury, but there is no established treatment for acute respiratory distress syndrome (ARDS) caused by NO2 inhalation.Case Presentation: A 35‐year‐old man was accidentally exposed to NO2 fumes and presented to the emergency department. On admission, his oxygen saturation was 87% on ambient air and he was diagnosed with ARDS caused by NO2 inhalation and immediately intubated; however, hypoxemia and hypercapnia were not ameliorated. Hence, veno‐venous extracorporeal membrane oxygenation (V‐V ECMO) was introduced and the ventilator settings were set for lung‐protective ventilation. Methylprednisolone was also administered. After the initiation of these treatments, oxygenation gradually improved. Therefore, ECMO was weaned off on day 11 and he was extubated on day 12.Conclusion: Lung injury caused by NO2 inhalation can cause ARDS, and lung‐protective ventilation with V‐V ECMO induction, as well as glucocorticoid administration, may be effective for this condition.


  • Open Access

    Comparison of the efficacy of continuous intravenous infusion versus intramuscular injection of epinephrine for initial anaphylaxis treatment

    by Kenji Fujizuka, Mitsunobu Nakamura, Junichi Tamura, Keiko Kawai‐Kowase

    Aim: Continuous intravenous (CIV) infusion of epinephrine for the treatment of anaphylaxis may be required if symptoms do not improve after intramuscular (IM) injection. As CIV infusion permits precise dose adjustment, we compared treatment course and adverse events following CIV infusion and IM injection of epinephrine for the management of anaphylaxis.Methods: Medical records of patients, who were treated for anaphylaxis with epinephrine, were 18 years or older, and were admitted to our department from April 2005 to March 2016, were retrospectively reviewed. The cases were categorized as CIV infusion or IM injection, and treatment course and outcomes were compared between the two groups.Results: Of the 142 eligible cases, there were 78 in the CIV infusion group and 64 in the IM injection group. The CIV infusion group had lower systolic blood pressure, more respiratory symptoms, and higher Acute Physiology and Chronic Health Evaluation II (APACHE II) scores, but required a lower total dose of epinephrine, had fewer adverse events after epinephrine administration, and showed lower incidence of biphasic reactions. In addition, compared with the IM injection group, time to administration of epinephrine was significantly longer (P < 0.001), but time to resolution of symptoms, both from contact and epinephrine administration, was significantly shorter (P < 0.01 and P = 0.03, respectively).Conclusion: Continuous intravenous infusion of epinephrine for the treatment of anaphylaxis may be safe, has fewer adverse events, improves symptoms, and is relatively easy to administer under ready conditions. CIV infusion of epinephrine may also reduce the incidence of biphasic reactions.


  • Open Access

    Corynebacterium ulcerans pneumonia treated with venovenous extracorporeal membrane oxygenation: a case report

    by Yoshihiko Takahashi, Shu Utsumi, Gaku Sugiura, Kenji Fujizuka, Hiroyuki Suzuki, Mitsunobu Nakamura


  • Open Access

    Effects of evidence-based ICU care on long-term outcomes of patients with sepsis or septic shock (ILOSS): protocol for a multicentre prospective observational cohort study in Japan

    by Keibun Liu, Toru Kotani, Kensuke Nakamura, Takai Chihiro, Yasunari Morita, Kenzo Ishii, Kenji Fujizuka, Daisetsu Yasumura, Daisuke Taniguchi, Tomohiro Hamagami, et al.

    Introduction Sepsis is not only the leading cause of death in the intensive care unit (ICU) but also a major risk factor for physical and cognitive impairment and mental disorders, known as postintensive care syndrome (PICS), reduced health-related quality of life (HRQoL) and even mental health disorders in patient families (PICS-family; PICS-F). The ABCDEF bundle is strongly recommended to overcome them, while the association between implementing the bundle and the long-term outcomes is also unknown. Methods and analysis This is a multicentre prospective observational study at 26 ICUs. All consecutive patients between 1 November 2020 and 30 April 2022, who are 18 years old or older and expected to stay in an ICU for more than 48 hours due to sepsis or septic shock, are enrolled. Follow-up to evaluate survival and PICS/ PICS-F will be performed at 3, 6 and 12 months and additionally every 6 months up to 5 years after hospital discharge. Primary outcomes include survival at 12 months, which is the primary outcome, and the incidence of PICS defined as the presence of any physical impairment, cognitive impairment or mental disorders. PICS assessment scores, HRQoL and employment status are evaluated. The association between the implementation rate for the ABCDEF bundle and for each of the individual elements and long-term outcomes will be evaluated. The PICS-F, defined as the presence of mental disorders, and HRQoL of the family is also assessed. Additional analyses with data up to 5 years follow-up are planned. Ethics and dissemination This study received ethics approvals from Saiseikai Utsunomiya Hospital (2020-42) and all other participating institutions and was registered in the University Hospital Medical Information Network Clinical Trials Registry. Informed consent will be obtained from all patients. The findings will be published in peer-reviewed journals and presented at scientific conferences. Trial registration number UMIN000041433.